August 6, 2020 10:25 AM EDT
R&D

Pfiz­er's Lor­bre­na bests Xalko­ri in PhI­II read­out — is it a po­ten­tial suc­ces­sor?

Max Gelman

Senior Editor

Pfiz­er has long pinned hopes on lor­la­tinib as be­ing a suc­ces­sor to Xalko­ri for ALK-pos­i­tive non-small cell lung can­cer, and the phar­ma re­leased da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times